DGAP-Adhoc: Fresenius SE:Successful 2008 − Financial

Fresenius SE / Final Results

19.02.2009 

Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

Successful 2008 &#8722; Financial targets fully met or exceeded &#8722;
Positive outlook for 2009
Group sales increased by 13 % in constant currency and by 9 % at actual
rates to EUR 12,336 million (2007: EUR 11,358 million). Organic sales
growth was 8 %. Acquisitions contributed a further 5 %, mainly driven by
the consolidation of APP Pharmaceuticals as from September 1, 2008.
Currency translation had a negative impact of 4 %.
The Group's US GAAP annual financial results as of December 31, 2008
include special items relating to the acquisition of APP Pharmaceuticals.
The single-largest of those items is the full depreciation of acquired
in-process R&D activities. Adjusted earnings represent the Group's business
operations in the reporting period.
Adjusted Group operating income (EBIT, before special items) grew by 11 %
in constant currency and by 7 % at actual rates to EUR 1,727 million (2007:
EUR 1,609 million). Group EBIT (including special items) was EUR 1,477
million.
Adjusted Group net income grew by 13 % in constant currency and by 10 % at
actual rates to EUR 450 million (2007: EUR 410 million). Adjusted earnings
per ordinary share increased to EUR 2.85 and adjusted earnings per
preference share increased to EUR 2.86 (2007: ordinary share EUR 2.64,
preference share EUR 2.65). This represents an increase of 11 % for both
share classes in constant currency.
Group net income (including special items) was EUR 270 million or EUR 1.71
per ordinary share and EUR 1.72 per preference share.
The Management Board will propose to the Supervisory Board a dividend
increase to EUR 0.70 per ordinary share (2007: EUR 0.66) and to EUR 0.71
per preference share (2007: EUR 0.67) for fiscal year 2008.
For 2009, Fresenius projects further improvements in its financial results:
Group sales are expected to grow by more than 10 % in constant currency.
Organic growth is projected to be in a 6 to 8 % range. Adjusted net income
(before special items) is expected to increase by aproximately 10 % in
constant currency. The special items relate to the mark-to-market
accounting of both the mandatory exchangeable bond (MEB) and the contingent
value right (CVR) and are not cash relevant.




(Financial statements according to US GAAP)

The Management Board

Bad Homburg v.d.H., February 19, 2009

End of note
DGAP 19.02.2009 
---------------------------------------------------------------------------
Language:     English
Issuer:       Fresenius SE
              Else-Kröner-Straße 1
              61352 Bad Homburg v.d.H.
              Deutschland
Phone:        +49 (0)6172 608-2485
Fax:          +49 (0)6172 608-2488
E-mail:       ir-fre@fresenius.com
Internet:     www.fresenius.com
ISIN:         DE0005785638, DE0005785604
WKN:          578563, 578560
Indices:      MDAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard), Düsseldorf,
              München; Freiverkehr in Berlin, Hannover, Stuttgart, Hamburg;
              Terminbörse EUREX
End of News                                     DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: Fresenius SE:Successful 2008 − Financial targets fully met or exceeded − Positive outlook for 2009
